vs
Side-by-side financial comparison of SELLAS Life Sciences Group, Inc. (SLS) and Virax Biolabs Group Ltd (VRAX). Click either name above to swap in a different company.
SELLAS Life Sciences Group, Inc. is the larger business by last-quarter revenue ($79.0K vs $76.5K, roughly 1.0× Virax Biolabs Group Ltd). Virax Biolabs Group Ltd runs the higher net margin — -3809.4% vs -12108.9%, a 8299.4% gap on every dollar of revenue.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative cancer immunotherapies for patients with unmet medical needs. Its core pipeline targets both hematological malignancies and solid tumors, with lead product candidates addressing indications like acute myeloid leukemia, primarily serving markets across North America.
Virax Biolabs Group Ltd is a global biotechnology company specializing in the development, production and distribution of in vitro diagnostic test kits. Its core product portfolio covers testing solutions for infectious diseases and immunological conditions, serving clinical institutions, research laboratories and commercial partners across multiple global regions.
SLS vs VRAX — Head-to-Head
Income Statement — Q1 FY2024 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $79.0K | $76.5K |
| Net Profit | $-9.6M | $-2.9M |
| Gross Margin | — | 13.7% |
| Operating Margin | -12208.9% | -3537.5% |
| Net Margin | -12108.9% | -3809.4% |
| Revenue YoY | — | — |
| Net Profit YoY | 13.8% | — |
| EPS (diluted) | $-0.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.7M | — |
| Total Assets | $24.4M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | — | — | ||
| Q1 24 | $18.4M | — |
| Q3 24 | — | — | ||
| Q1 24 | $9.7M | — |
| Q3 24 | — | — | ||
| Q1 24 | $24.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.8M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | — | — | ||
| Q1 24 | $-10.8M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
